Sponsored by:

Molecular Imaging

Whole-body PET shows how naloxone blocks opioids
By Will Morton
PET imaging has shown for the first time how the opioid overdose treatment naloxone blocks neuroreceptors throughout the body.
May 9, 2025
Naloxone2 Thumbnail
Shine to buy Lantheus’ SPECT business
By AuntMinnie.com staff writers
Medical isotope developer Shine Technologies has entered an agreement to acquire Lantheus Holdings’ SPECT business.
May 7, 2025
Acquisitions
Siemens posts strong revenue growth in Q2 2025
By AuntMinnie.com staff writers
Siemens Healthineers reported revenue growth in the second quarter of 2025 compared to last year.
May 7, 2025
Siemens2
SPECT/CT MPI may guide medical therapy in CAD patients
By Will Morton
SPECT/CT myocardial perfusion imaging can identify patients with coronary artery disease who are more likely to benefit from specific therapies.
May 7, 2025
Screenshot 2025 05 06 141932
FDA clears GE's new dual-head SPECT/CT system
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) has cleared GE HealthCare's (GEHC) new dual-head SPECT/CT system, Aurora.
May 5, 2025
Gehc
PET/MRI and DECT show abnormalities in long COVID patients
By Will Morton
Patients with long COVID show lung and heart abnormalities on PET/MRI and dual-energy CT imaging.
May 5, 2025
Myocardial involvement. Representative examples show fused PET/MRI images in patients with findings suggestive of myocarditis. (A and B) Short-axis view of increased F-18 FDG uptake in basal septum segments (A), colocalized with area of increased T2 values (B) on parametric mapping. (C and D) Prominent F-18 FDG uptake in middle anterolateral and inferolateral walls (C), matching area of increased T1 values (D). (E and F) Short-axis views of avid F-18 FDG uptake in basal inferior and inferolateral walls (E), matching areas of increased extracellular volume (F). SUV scale is 0-5 g/mL.
IMV: PET/CT service contracts are a key aspect of system ownership
By Davin Korstjens
May 2, 2025
Cardiac Pet
Controversy clouds nuclear medicine bill
By Will Morton
Radiology societies and patient advocates are at odds over a bill in the U.S. Congress.
May 1, 2025
Congress
FDA rejects NDA for Telix’s Pixclara
By AuntMinnie.com staff writers
The FDA has ruled that Telix's New Drug Application (NDA) for TLX101-CDx (Pixclara) cannot be approved in its current form.
April 29, 2025
Glioma Letters Brain
ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
By Will Morton
Advances in brain PET imaging combined with new treatments for Alzheimer’s have given rise to a new concept of "neurotheranostics."
April 29, 2025
A conceptual framework for neurotheranostics.
ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
By Maryam Payne
Evaluating increased rib uptake on F-18 DCFPyL PET/CT in prostate cancer patients may lead to false positives.
April 28, 2025
Pet Ct Machine
SPECT/CT predicts overall survival in Pluvicto patients
By Will Morton
New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.
April 25, 2025
Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
Page 1 of 604
Next Page